First Header Logo Second Header Logo

Connection

David Caudell to Histone Deacetylase Inhibitors

This is a "connection" page, showing publications David Caudell has written about Histone Deacetylase Inhibitors.
Connection Strength

0.297
  1. Vieson MD, Gojmerac AM, Khan D, Dai R, van Duzer JH, Mazitschek R, Caudell DL, Liao X, Luo XM, Reilly CM. Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice. Histol Histopathol. 2017 Dec; 32(12):1317-1332.
    View in: PubMed
    Score: 0.146
  2. Regna NL, Chafin CB, Hammond SE, Puthiyaveetil AG, Caudell DL, Reilly CM. Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo. Clin Immunol. 2014 Mar; 151(1):29-42.
    View in: PubMed
    Score: 0.118
  3. Regna NL, Vieson MD, Gojmerac AM, Luo XM, Caudell DL, Reilly CM. HDAC expression and activity is upregulated in diseased lupus-prone mice. Int Immunopharmacol. 2015 Dec; 29(2):494-503.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.